Tracleer Articles
FTC files Amicus Brief, saying improper use of restricted drug distribution programs may impede generic competition
13 March 2013
New Zealand approves funding of sildenafil for Raynaud's phenomenon and bosentan for children with PAH
28 January 2013
New Zealand updates on Tracleer and sildenafil listing
21 November 2012
Proposal in relation to Actelion's Tracleer in New Zealand
1 October 2012
Novartis cancer drug imatinib shows efficacy in PAH
26 September 2011
Preliminary safety data relating to bladder cancer risk of Takeda’s Actos under review by US FDA; Actelion subpoenaed over Tracleer marketing
20 September 2010
Actelion buys option to acquire privately-held Trophos; posts strong 2nd-qtr 2010 results
20 July 2010
Actelion shares plunge as Tracleer fails to meet primary endpoint in idiopathic pulmonary fibrosis
2 March 2010
Soaring Tracleer sales boost Actelion’s 2009 financial results
19 February 2010
Actelion’s Tracleer gets US label extension
10 August 2009
Tracleer plus tadalafil boosts 6MWD
28 May 2009
IDSMB gives go ahead for Actelion IPS trial
11 May 2009
Actelion's 1st-qtr profit doubles on forex effect
27 April 2009
FDA asks for REMS before expanding Tracleer use
9 March 2009
2008 profit doubles for Actelion on 2007 costs
2 March 2009
Actelion profit up five-fold in 2008 so far
3 November 2008
Correction: Actelion's Tracleer
18 August 2008
Correction: Actelion's Tracleer
18 August 2008
Tracleer approved in EU for PAH FC II
11 August 2008
Actelion recovers from poor first quarter
4 August 2008
Actelion's Tracleer shows benefit in FC II PAH
7 July 2008
Expanded indication for Actelion's PAH drug
7 July 2008
Actelion
5 May 2008
Stephamie Kelly named Actelion UK/Ireland brand manager
31 March 2008
Actelion's 2007 profit falls 47% on costs
3 March 2008
Actelion's FY 2007 net revenues beat forecasts
28 January 2008
Strong PAH data for Tracleer plus sildenafil
29 October 2007
Stock Commentary - Europe - week to October 22, 2007
29 October 2007
Actelion's 9-month net profit declines to $30.6M
29 October 2007
Stock Commentary - Europe - week to October 15, 2007
22 October 2007
Tracleer delays PAH worsening in WHO-defined class II patients
10 September 2007
Stock Commentary - Europe - week to June 18, 2007
25 June 2007
Actelion's 1st-qtr 2007 loss deepens 179%
30 April 2007
Three new drugs get nod from EMEA's CHMP
2 April 2007
Stock Commentary - Europe - week to March 12, 2007
26 March 2007
Gilead's ambrisentan NDA accepted by FDA
26 February 2007
Stock Commentary - Europe - week to Jan 8, 2007
15 January 2007
Stock Commentary - Europe - week to Jan 1, 2007
8 January 2007
Tracleer shows promise in class II PAH patients
22 December 2006
Stock Commentary - Europe - week to Sept 4, 2006
11 September 2006
Actelion sees 1st-half sales of 437.1M SwFr
31 July 2006
Stock Commentary - Europe - week to May 29, 2006
5 June 2006
Bosentan performs well in IPF study
5 June 2006
Actelion beats 1st-qtr 2006 forecasts
1 May 2006
Stock Commentary - Europe - week to April 10, 2006
17 April 2006
Mixed trial results for Actelion's Tracleer
5 December 2005
Actelion's Tracleer of benefit as Eisenmenger's therapy
5 December 2005
Actelion's R&D day: eight compounds in pipeline
19 September 2005
Expanded label for CoTherix' Ventavis
5 September 2005
Tracleer effective in pediatric PAH
22 August 2005
Actelion's Tracleer meets Ph III endpoint
15 August 2005
Actelion ups guidance on good 1st half
8 August 2005
Tracleer shows benefit in heart defect-PAH
18 July 2005
Encysive plans to sell Thelin in Europe
27 June 2005
Stock Commentary - New York
13 June 2005
Actelion launches Tracleer in Japan
13 June 2005
Actelion sees 1sr-qtr net profit leap 52%
26 April 2005
Japan OKs Actelion's Tracleer for PAH
18 April 2005
CoTherix' Ventavis debuts in USA
28 March 2005
Actelion's Tracleer gets Japanese go-ahead
7 March 2005
Actelion expects a springtime launch for Tracleer in Japan
28 February 2005
Encysive's Thelin study meets endpoints
21 February 2005
Myogen alters ambrisentan guidance
14 February 2005
Orphan Drug status for Encysive's Thelin
22 November 2004
Actelion stops Veletri study; shares hit
15 November 2004
Actelion's Tracleer improves quality of life
1 November 2004
Actelion posts 1st-half sales growth of 63%
2 August 2004
US Rx lottery ahead of Medicare benefit
5 July 2004
Actelion's Tracleer to benefit from new law?
5 July 2004
Actelion sees record revenues for 1st-qtr
3 May 2004
Actelion's target price bumped up
2 February 2004
Actelion aiming high as profits grow
3 November 2003
Actelion's Tracleer active in PAH
8 September 2003
Tracleer continues to drive Actelion profits
4 August 2003
Bosentan gets COMP backing for sclerosis
21 April 2003
Actelion files Japan NDA for Tracleer
14 April 2003
Actelion "could turn profit" by end-2003
24 February 2003
Actelion's Tracleer ahead of forecasts
3 February 2003
Analyst plays down Viagra threat to Actelion
27 January 2003
Actelion
19 August 2002
Actelion's Tracleer effective in digital ulcer prevention
19 August 2002
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
